Promising new agents for treatment of patients with colorectal cancer

Related Experiment Video

Updated: Aug 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

D D Von Hoff1

  • 1Institute for Drug Development, Department of Medicine, The University of Texas Health Science Center at San Antonio, 78245, USA.

Seminars in Oncology
|October 24, 1998
PubMed

Insights

New agents show promise for treating colorectal cancer, including LY 231514 and capecitabine. Research also explores agents like 6-hydroxymethylacylfulvene and cyclooxygenase inhibitors for prevention and treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Colorectal cancer remains a significant global health challenge.
  • Existing treatments have limitations, necessitating the development of novel therapeutic strategies.
  • Understanding the molecular pathways involved in colorectal cancer progression is crucial for targeted therapy development.

Purpose of the Study:

  • To review emerging therapeutic agents for colorectal cancer.
  • To highlight agents with demonstrated clinical and preclinical activity.
  • To explore potential chemopreventive strategies targeting polyp formation.

Main Methods:

  • Literature review of recent studies on colorectal cancer therapeutics.
  • Analysis of clinical trial data for agents like LY 231514 and capecitabine.
  • Evaluation of preclinical data for novel compounds such as 6-hydroxymethylacylfulvene (HMAF) and ONYX-015.

Main Results:

  • The multitargeted antifolate LY 231514 and thymidylate synthesis inhibitor capecitabine exhibit promising clinical activity.
  • Several agents, including 6-hydroxymethylacylfulvene (HMAF), LY 295501, bizelesin, and ONYX-015, show promising preclinical efficacy.
  • Cyclooxygenase (COX) inhibitors are being investigated for their potential in preventing colorectal polyp formation.

Conclusions:

  • Novel therapeutic agents offer new hope for colorectal cancer treatment.
  • A combination of targeted therapies and chemopreventive strategies may improve patient outcomes.
  • Continued research into these agents is warranted to further combat colorectal cancer.

More Related Videos

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Subcutaneous Injection of Human Colorectal Cancer Cells in Athymic Nude Mice to Evaluate Antitumor Efficacy06:35

Subcutaneous Injection of Human Colorectal Cancer Cells in Athymic Nude Mice to Evaluate Antitumor Efficacy

Published on: July 8, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...